For US residents only.

How Treatment May Help


How Effective is TASIGNA® (nilotinib) vs GLEEVEC?

In a clinical trial that compared TASIGNA vs GLEEVEC® (imatinib mesylate) in newly diagnosed Ph+ CML patients, TASIGNA was shown to be more effective based on several different criteria:

Major Molecular Response (MMR)2

Twice as many patients who took TASIGNA achieved a major molecular response (MMR) one year into the clinical trial as patients who took GLEEVEC.

Fewer Patients Progressed to Accelerated or Blast Crisis1

For 99% of patients who took TASIGNA, their Ph+ CML did not progress to the accelerated or blast crisis phase after 5 years, compared to 95% of GLEEVEC treated patients.


Based on Kaplan-Meier estimates of time to progression to AP or BC on core treatment (full analysis set) without clonal evolutions.

Higher Estimated Rates of Survival1,2

The estimated overall rates of survival 5 years after the start of the clinical trial were higher for patients on TASIGNA than GLEEVEC (93.7% versus 91.7%). Median overall survival (OS) was not reached in either arm during the ENESTnd study.


  1. Data on file. Study no. CAMN107A2303. Novartis Pharmaceuticals Corp; 2014.
  2. Tasigna [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2017.